Addex Therapeutics
12, Chemin Des Aulx
1228 Plan-les-Ouates
Geneva
Tel: 41-22-884-1555
Fax: 41-22-884-1556
Website: http://www.addexpharma.com/
Email: info@addexpharma.com
303 articles about Addex Therapeutics
-
Addex to Present at the Bio-Europe Spring 2024 Conference
3/14/2024
Addex Therapeutics announced that CEO, Tim Dyer, will present at the Bio-Europe Spring 2024 conference taking place March 18 - 20, 2024 in Barcelona, Spain.
-
Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
1/31/2024
Addex Therapeutics announced that the company has entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, ADSs having an aggregate offering price of up to $2.1 million through H.C. Wainwright as its sales agent.
-
Addex to Present at the Swiss Equities Baader Conference
1/9/2024
Addex Therapeutics announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at the Swiss Equities Baader Conference being held in Bad Ragaz, Switzerland, January 10-12, 2024.
-
Addex to Present at Biotech Showcase™ 2024
1/5/2024
Addex Therapeutics announced that Tim Dyer, Chief Executive Officer, will present at Biotech Showcase being held in San Francisco, January 8-10, 2024.
-
Addex Shareholders Approve All Resolutions at Extraordinary General Meeting
12/20/2023
Addex Therapeutics announced that its shareholders approved, with a large majority, all of the proposals of the board of directors at its Extraordinary General Meeting held on December 19, 2023.
-
Addex Creates Treasury Shares - December 14, 2023
12/14/2023
Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that 15,300,000 new registered shares at a nominal value of CHF 0.01 have been issued and fully subscribed by Addex Pharma S.A, its 100% wholly-owned subsidiary.
-
Addex Reports Q3 2023 Financial Results and Provides Corporate Update
11/29/2023
Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported its Q3 2023 financial results for the period ended September 30, 2023 and provides a corporate update.
-
Addex Convenes Extraordinary General Meeting
11/28/2023
Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that an Extraordinary General Meeting is convened and will take place on Tuesday December 19, 2023, at 11:00 am CET at the Campus Biotech, Chemin des Mines 9, 1202 Geneva.
-
Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023
11/23/2023
Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that that it will issue its Third Quarter 2023 Financial Results on November 29, 2023.
-
Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients
11/14/2023
Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that the last patient has been randomized in Cohort 2 of the ADX71149 Phase 2 epilepsy clinical study.
-
Addex Regains Nasdaq Listing Compliance
11/8/2023
Addex Therapeutics announced it had received written notification from The Nasdaq Stock Market LLC that it has regained compliance with the minimum bid price requirement of $1.00 per ADS under Nasdaq Listing Rule 5550 and currently meets all other applicable criteria for continued listing.
-
Addex Announces Participation in the Bio-Europe 2023 Conference
11/2/2023
Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that Tim Dyer, Chief Executive Officer, and Dr. Mikhail Kalinichev, Head of Translational Science, will be attending the Bio-Europe 2023 Conference in Munich, Germany.
-
Addex Announces Plan to Implement ADS Ratio Change
10/6/2023
Addex Therapeutics announced that it plans to change the ratio of its American Depositary Shares to its ordinary shares from the current ADS Ratio of one ADS to six ordinary shares to a new ADS Ratio of one ADS to one hundred and twenty ordinary shares.
-
Addex mGlu2 NAM Cognition Program Receives €4 Million Grant
9/20/2023
Addex Therapeutics announced that it has led a consortium which has been awarded a €4 million Eurostars grant to support its metabotropic glutamate 2 receptor negative allosteric modulator program for mild neurocognitive disorder.
-
From reversing overdose to blocking cravings, the biopharma industry is looking at a range of possible solutions to addiction.
-
Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
9/6/2023
Addex Therapeutics announced that Tim Dyer, Chief Executive Officer, will be attending the H.C. Wainwright 25th Annual Global Investment Conference in New York.
-
Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024
9/5/2023
Addex Therapeutics announced that the ADX71149 Phase 2 epilepsy clinical study is progressing well, with Cohort 1 completed and 80% of patients recruited into Cohort 2.
-
Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update
8/10/2023
Addex Therapeutics reported its half-year and second quarter financial results for the periods ended June 30, 2023 and provided a corporate update.
-
Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration
8/3/2023
Addex Therapeutics announced that its collaboration agreement with Indivior PLC for the discovery of novel oral gamma-aminobutyric acid subtype B positive allosteric modulator drug candidates for the treatment of substance use disorder has been extended until June 30, 2024.
-
Addex Reports Q1 2023 Financial Results and Provides Corporate Update
5/11/2023
Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.